Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 22:48 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Anti-TNFα to Delay or Prevent Progression to Stage 3 T1D
NCT04729296 · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · PHASE2 · withdrawn · last registry update 2021-12-02 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Withdrawn due to COVID-19 related clinical limitations” | – | Registry record, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against TNF within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2022-09-19Also stopped (terminated): Mario Negri Institute for Pharmacological Research, Tocilizumab + Etanercept (NCT03100253)
- 2022-08-16Results posted on the registry: National Institute of Allergy and Infectious Diseases (NIAID), Infliximab + Methylprednisolone (NCT02495077)
- 2022-08-09Also stopped (withdrawn): Children's Hospital of Fudan University, Infliximab (NCT04530877)
- 2022-07-20Also stopped (withdrawn): Hospices Civils de Lyon, Infliximab + Cyclophosphamide (NCT03088293)
- 2022-07-14Results posted on the registry: Janssen Research & Development, LLC, Golimumab + Placebo (NCT02846545)
- 2022-05-18Phase 3 first posted: Abu Dhabi Stem Cells Center, Anti-TNF + JAK inhibitor (NCT05379322)
- 2022-05-04Results posted on the registry: Merck Sharp & Dohme LLC, Golimumab + Placebo (NCT03253796)
- 2022-04-15Results posted on the registry: Incyte Corporation, Ruxolitinib + Extracorporeal photopheresis (ECP) (NCT03112603)
- 2021-12-28Results posted on the registry: Pfizer, PF-06687234 + Placebo (NCT03269695)
- 2021-12-28Also stopped (terminated): Pfizer, PF-06687234 + Placebo (NCT03269695)
- 2021-12-03Results posted on the registry: Tufts Medical Center, Infliximab (NCT04425538)
- 2021-12-03Results posted on the registry: University of California, San Diego, IVIG + Infliximab (NCT03065244)
- 2021-10-19Results posted on the registry: Emory University, Infliximab (NCT03006393)
- 2021-10-01Also stopped (terminated): Schneider Children's Medical Center, Israel, Infliximab (NCT03209232)
- 2021-09-16Phase 3 first posted: Bio-Thera Solutions, BAT2506 + EU Simponi (NCT05046431)
- 2021-08-13Results posted on the registry: Hoffmann-La Roche, Etrolizumab + Infliximab (NCT02136069)
- 2021-08-10Phase 3 first posted: Assistance Publique - Hôpitaux de Paris, Fecal Microbiota Transplantation (FMT) + Sham-transplantation (placebo) (NCT04997733)
- 2021-07-28Results posted on the registry: University Health Network, Toronto, Infliximab (NCT02363738)
- 2021-07-23Phase 3 first posted: Children's Hospital Medical Center, Cincinnati, Infliximab precision dosing (NCT04974099)
- 2021-07-19Results posted on the registry: AbbVie, ABBV-3373 + Placebo for ABBV-3373 (NCT03823391)
- 2021-07-01Results posted on the registry: Guy's and St Thomas' NHS Foundation Trust, Golimumab (NCT03124121)
- 2021-06-23Also stopped (withdrawn): UCB Biopharma SRL, Certolizumab pegol + Adalimumab (NCT04643483)
- 2021-05-24Phase 3 first posted: University of California, San Diego, Infliximab + Anakinra (NCT04898231)
- 2021-03-12Also stopped (withdrawn): Children's Hospital of Fudan University, IVIG + Aspirin (NCT04535518)
- 2021-03-04Results posted on the registry: Janssen Scientific Affairs, LLC, Infliximab + Golimumab (NCT01804166)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision